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Multi-parametric MRI (mp-MRI) rather than trans-rectal 
ultrasound (TRUS)-guided prostate biopsy is becoming 
more popular as the initial evaluation of a patient with 
an elevated PSA or an abnormal prostate exam.  If a 
cancer suspicious region (CSR) is detected by mp-
MRI, the patient may undergo imaging-guided targeted 
biopsy with or without a standard systematic biopsy.  
Recently, there has been an increasing trend for 
patients to undergo focal treatment for focal tumors to 
avoid potential complications of surgery or radiation 
therapy.  The question is whether targeted biopsy 
alone is sufficient to determine if the patient's tumor is 
focal.  The objectives of this study are to determine the 
detection rate of prostate cancer (PCa) Gleason score 
(GS) ≥ 7 in the opposite side of the prostate from the 
CSRs and to determine if it is necessary to perform a 
standard systematic prostate biopsy in addition to a 
target biopsy.
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Sixty-eight consecutive men with elevated PSA, at 
least one CSR detected on mp-MRI on a single side of 
the prostate (right or left, not both) and no TRUS-
guided biopsy within the preceding 3 years underwent 
MRI/US fusion-guided biopsy of CSRs and standard 
systematic prostate biopsy (12 cores).  Histopathology 
results, including GS, location of cancer and 
percentage of tumor involving positive cores, as well as 
patients' clinical information, including age, PSA, PSA 
density and prostate volume, were recorded.  Two 
experienced GU radiologists retrospectively reviewed 
all mp-MRI studies blindly. The assessment included 
but was not limited to location and PI-RADS scores of 
CSRs.  The findings from the imaging review were 
correlated with the histopathology results.  Statistical 
significance of differences in clinical information 
between patients with positive and negative biopsies 
on the opposite side from the target lesion was 
evaluated using Student’s T-test.
On confirmatory MRI/US fusion-guided targeted biopsy, 
56 of 68 patients had biopsy-proven PCa (82%).  
Among them, 47 patients had PCa GS 7 (69%), 12 had 
PCa GS 8 (18%) and 9 had GS 9 (13%).  Nine of 68 
patients (13%) had PCa GS ≥ 7 on the opposite side of 
the prostate from the target lesions (GS 7, n=5 and GS 
8, n=4) detected by the standard systematic biopsy.  
The mean percentage of the positive core of PCa for 
GS 7 was 40% and for GS 8 was 25%. Retrospective 
review of these patients’ mp-MRI studies detected 
corresponding CSRs with PI-RADS score 3 on the 
opposite side from the target lesions in 3 of 9 patients. 
There was no statistically significant difference in 
patients' age, PSA, PSA density and prostate volume 
between patients with or without PCa GS ≥ 7 on one 
side (n=57) or both sides (n=9) of the prostate.  
Addition of standard systematic prostate biopsy to 
targeted biopsy in patients with elevated PSA and no 
prior systematic prostate biopsy within the preceding 
3 years detected PCa GS ≥ 7 on the opposite side of 
the prostate from the target lesions (with no 
significant abnormalities on mp-MRI) in 13% of 
patients.  This result may influence treatment 
choices, particularly for those patients considering 
focal therapy for PCa.
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Straight arrow: Lesion readily visualized on mpMRI. Targeted biopsy 
confirmed PCa GS 7 (4+3), 60% in Left Base. Curved arrow: Systematic 
TRUS biopsy picks up PCa GS 7 (4+3), 20% in Right Base without 
evidence on mpMRI
Standard systematic biopsies should be added to US/MRI fusion 
prostate biopsies in patients with no prior or ≥3 years prior TRUS 
biopsy. 
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